Expert Analysis

Antiretroviral Drug Resistance

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Antiretroviral Drug Resistance

Faculty:

Eric S. Daar, MD
Daniel R. Kuritzkes, MD
Andrew R. Zolopa, MD

CME CREDIT INFORMATION

Release Date: 03/28/08

Expiration Date: 03/27/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe new data on strategies to reduce drug resistance associated with antiretroviral therapy for prevention of mother-to-child HIV transmission
Discuss recent findings on the impact of minority variants on virologic response to NNRTI-based regimens
Summarize new data on novel approaches to evaluate viral tropism
Cite recent insights into resistance from studies of maraviroc, darunavir/ritonavir, lopinavir/ritonavir, and etravirine

Topics covered include:

Strategies to Reduce Drug Resistance Associated With Use of Antiretroviral Therapy to Prevent MTCT
ACTG A5146: PI Dose Adjustment for Patients With a Low Pharmacologic Inhibitory Quotient
ACTG 5077: Comparison of HIV Sequences in Plasma and Genital Compartments
Impact of Minority NNRTI-Resistant Variants on Virologic Response to NNRTI-Based Therapy
Novel Approaches to Evaluate HIV-1 Chemokine Coreceptor Tropism
Causes of Failure and Resistance in MERIT and MOTIVATE
TITAN: Resistance Following Failure of Darunavir/Ritonavir vs Lopinavir/Ritonavir in Treatment-Experienced Patients
Virtual Phenotype Clinical Cutoffs for Etravirine Susceptibility

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.